创新的配方用于眼部输送辅酶Q10的配方
Sara Signorini1, Silvia Pescina1, Caterina Ricci2
1ADDRes Lab, Department of Food and Drug, University of Parma, Parco Area Delle Scienze 27/a, 43124, Parma, Italy.
Drug delivery and translational research
|December 7, 2024
概括
这项研究开发了一种新的眼部输送系统,使用TPGS-CoQ10微粒在聚合物膜内. 这一策略提高了CoQ10的生物可用性,用于治疗视网膜神经退行性疾病.
科学领域:
- 眼科医生 眼科 眼科
- 纳米技术纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 辅酶Q10 (CoQ10) 是线粒体功能的重要抗氧化剂.
- CoQ10的神经保护性质对眼部神经退行性疾病有希望.
- 眼睛的后部部段 CoQ10 的有效输送受到眼睛屏障的阻碍.
研究的目的:
- 开发用于CoQ10的新型眼部输送策略.
- 为了提高CoQ10在眼睛后部的生物可用性.
- 为了实现可控释放CoQ10的持续治疗效果.
主要方法:
- 聚合物D-α-托科菲尔聚乙烯甘1000酸盐 (TPGS) 的微粒被配制为加载CoQ10.
- 使用动态光散射 (DLS) 和小角度X射线散射 (SAXS) 进行了菌根的特征鉴定.
- 在猪膜和膜上进行的ex vivo研究评估了膜的保留和透.
- 装载的小粒被纳入一个交联的聚合物薄膜中,用于控制释放和生物相容性测试 (HET-CAM测试).
主要成果:
- TPGS小粒成功加载并增加了CoQ10溶解度和眼组织透率.
- 活体研究表明,菌在眼睛组织中的保留和透能力.
- 聚合物薄膜提供了TPGS和CoQ10的受控释放,并显示出良好的生物相容性.
- 活体研究证实了这种眼部输送平台的潜力.
结论:
- TPGS-CoQ10微粒是提高眼部生物可用性的有希望的策略.
- 开发的聚合物薄膜平台有助于控制释放,并证明生物相容性.
- 这种新型的输送系统有可能用于治疗需要辅酶Q10治疗的眼部神经退行性疾病.
相关概念视频
01:22Drug Delivery: Miscellaneous Routes
320
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
320
01:18Drug Delivery: Enteral Route
377
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
377
01:22Indirect-Acting Cholinergic Agonists: Pharmacokinetics
921
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
921
01:24Cholinergic Antagonists: Pharmacokinetics
411
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
411